Insulin and insulin-like growth factor-1 modulation of glucose transport in arterial smooth muscle cells: implication of GLUT-4 in the vasculature.
Insulin modulates many physiological processes in vascular smooth muscle cells (VSMC) such as contractility, proliferation, and ion homeostasis. However, hormonal modulation of glucose transport has not been explored in pure populations of these cells. This study demonstrates that insulin and insulin-like growth factor-1 (IGF-1) increase glucose transport in a7r5 clonal and freshly prepared Sprague-Dawley aortic (SDa) VSMC. In a7r5 cells, physiologic (10(-12) to 10(-9) mol/L) insulin concentrations increase transport by 8% to 15%, whereas supraphysiologic concentrations (10(-9) to 10(-6) mol/L) increase transport by up to 60% (P < .05 v no increase over all concentrations tested). In SDa cells, insulin was more potent, displaying maximum transport stimulation of 70% at 10(-8) mol/L (P < .05 v a7r5 cells). Insulin regulation of glucose transport occurs by a protein synthesis-independent pathway as 10 mumol/L cycloheximide was without effect. Insulin produces these effects within 20 min of treatment, and cytochalasin B (10 mumol/L) inhibits both basal and insulin-stimulated glucose transport by 93% and 96%, respectively. Stimulation of insulin receptors alone, with 2.5 pg/mL insulin receptor-specific antibody, stimulates glucose transport by 20%, suggesting transport can be stimulated by an IGF-1 receptor independent mechanism. However, IGF-1 is a more potent stimulator of transport in both cell lines studied, with maximal stimulation (10(-8) mol/L IGF-1) of 60% and 80% in a7r5 and SDa cells, respectively (P < .05 v 10(-8) mol/L insulin in both cell lines). Insulin stimulation of glucose transport is specific for [D+]-glucose; [L-]-glucose does not compete for transport.(ABSTRACT TRUNCATED AT 250 WORDS)
Department of Medicine, Wayne State University School of Medicine, Detroit, Michigan 48201.
P R
PR
Standley
K A
KA
Rose
D000818:Animals; D001011:Aorta / Q000166:cytology / Q000378:metabolism; D001158:Arteries / Q000166:cytology / Q000378:metabolism*; D001692:Biological Transport / Q000187:drug effects; D003513:Cycloheximide / Q000494:pharmacology; D003571:Cytochalasin B / Q000494:pharmacology; D003847:Deoxyglucose / Q000378:metabolism; D005947:Glucose / Q000037:antagonists & inhibitors / Q000378:metabolism*; D051275:Glucose Transporter Type 4; D007328:Insulin / Q000494:pharmacology*; D007334:Insulin-Like Growth Factor I / Q000494:pharmacology*; D009004:Monosaccharide Transport Proteins / Q000378:metabolism*; D009124:Muscle Proteins; D009131:Muscle, Smooth, Vascular / Q000166:cytology / Q000378:metabolism*; D051381:Rats; D017207:Rats, Sprague-Dawley; D011972:Receptor, Insulin / Q000378:metabolism
D051275:Glucose Transporter Type 4; D007328:Insulin; D009004:Monosaccharide Transport Proteins; D009124:Muscle Proteins; C495694:Slc2a4 protein, rat; D003571:Cytochalasin B; D007334:Insulin-Like Growth Factor I; D003513:Cycloheximide; D003847:Deoxyglucose; D011972:Receptor, Insulin; D005947:Glucose